These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
473 related items for PubMed ID: 16622900
1. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Gil-Rendo A, Zornoza G, García-Velloso MJ, Regueira FM, Beorlegui C, Cervera M. Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900 [Abstract] [Full Text] [Related]
2. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer. Fujii T, Yajima R, Tatsuki H, Kuwano H. Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160 [Abstract] [Full Text] [Related]
3. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. Pritchard KI, Julian JA, Holloway CM, McCready D, Gulenchyn KY, George R, Hodgson N, Lovrics P, Perera F, Elavathil L, O'Malley FP, Down N, Bodurtha A, Shelley W, Levine MN. J Clin Oncol; 2012 Apr 20; 30(12):1274-9. PubMed ID: 22393089 [Abstract] [Full Text] [Related]
4. FDG-PET for axillary lymph node staging in primary breast cancer. Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E. Eur J Nucl Med Mol Imaging; 2004 Jun 20; 31 Suppl 1():S97-102. PubMed ID: 15133635 [Abstract] [Full Text] [Related]
5. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, Spano G, Luini A, Intra M, Veronesi P, Berrettini A, Paganelli G. Ann Oncol; 2007 Mar 20; 18(3):473-8. PubMed ID: 17164229 [Abstract] [Full Text] [Related]
7. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Zornoza G, Garcia-Velloso MJ, Sola J, Regueira FM, Pina L, Beorlegui C. Eur J Surg Oncol; 2004 Feb 20; 30(1):15-9. PubMed ID: 14736517 [Abstract] [Full Text] [Related]
8. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging. Taira N, Ohsumi S, Takabatake D, Hara F, Takashima S, Aogi K, Takashima S, Inoue T, Sugata S, Nishimura R. Jpn J Clin Oncol; 2009 Jan 20; 39(1):16-21. PubMed ID: 18997183 [Abstract] [Full Text] [Related]
9. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients. Dalus K, Reitsamer R, Holzmannhofer J, Rendl G, Pirich C, Kronberger C, Rettenbacher L. Nuklearmedizin; 2011 Jan 20; 50(1):33-8. PubMed ID: 21336417 [Abstract] [Full Text] [Related]
10. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer. Ahn JH, Son EJ, Kim JA, Youk JH, Kim EK, Kwak JY, Ryu YH, Jeong J. Acta Radiol; 2010 Oct 20; 51(8):859-65. PubMed ID: 20670083 [Abstract] [Full Text] [Related]
11. Factors affecting the accuracy of 18F-FDG PET/CT in evaluating axillary metastases in invasive breast cancer. Kutluturk K, Simsek A, Comak A, Gonultas F, Unal B, Kekilli E. Niger J Clin Pract; 2019 Jan 20; 22(1):63-68. PubMed ID: 30666022 [Abstract] [Full Text] [Related]
13. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer. Machida Y, Kubota K, Katayama T, Toriihara A, Shibuya H. Eur J Surg Oncol; 2013 Jan 20; 39(1):26-30. PubMed ID: 23122913 [Abstract] [Full Text] [Related]
14. Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up. Agresti R, Crippa F, Sandri M, Martelli G, Tagliabue E, Alessi A, Pellitteri C, Maccauro M, Maugeri I, Barbara P, Rampa M, Moscaroli A, Ferraris C, Carcangiu ML, Bianchi G, Greco M, Bombardieri E. Breast; 2014 Aug 20; 23(4):334-40. PubMed ID: 24485802 [Abstract] [Full Text] [Related]
16. The roles of 18F-FDG-PET/CT and US-guided FNAC in assessment of axillary nodal metastases in breast cancer patients. Nakano Y, Noguchi M, Yokoi-Noguchi M, Ohno Y, Morioka E, Kosaka T, Takahashi T, Minato H. Breast Cancer; 2017 Jan 20; 24(1):121-127. PubMed ID: 27015862 [Abstract] [Full Text] [Related]
17. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van Geldere D, Meijer S, Lammertsma AA, Teule GJ. Ann Surg; 2002 Nov 20; 236(5):619-24. PubMed ID: 12409668 [Abstract] [Full Text] [Related]
18. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience. Kim J, Lee J, Chang E, Kim S, Suh K, Sul J, Song I, Kim Y, Lee C. World J Surg; 2009 May 20; 33(5):943-9. PubMed ID: 19259728 [Abstract] [Full Text] [Related]
19. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Kumar R, Zhuang H, Schnall M, Conant E, Damia S, Weinstein S, Chandra P, Czerniecki B, Alavi A. Nucl Med Commun; 2006 Mar 20; 27(3):231-6. PubMed ID: 16479242 [Abstract] [Full Text] [Related]